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Abstract
Background: Polycystic ovary syndrome (PCOS) is an endocrine disease closely related to several risk
factors for cardiovascular disease. An abnormal heart rate recovery (HRR), an easily-obtained measure
derived from exercise stress test and closely related to an increased risk for cardiovascular mortality, has
been recently described in PCOS women. A subclinical increase of the inflammation markers has been also
observed in the PCOS. This study was designed to study the relationships between HRR and inflammatory
markers in PCOS women.
Methods: Two-hundred forty-three young PCOS patients without known risk factors for cardiovascular
risk were enrolled. All patients underwent hormonal and metabolic profile, white blood cells (WBCs)
count and C-reactive protein (CRP). HRR was calculated as the difference between heart rate at peak
exercise and heart rate at first minute of the cool-down period. Abnormal HRR was defined as ≤18 beats/
min for standard exercise testing.
Results: Eighty-nine out of 243 patients presented abnormal HRR. Serum CRP (1.8 ± 0.7 vs. 1.1 ± 0.4 mg/
dl, p < 0.001) and WBCs (7.3 ± 1.8 vs. 6.6 ± 1.5 109 cells/l, p < 0.001) concentrations were significantly
higher in PCOS patients with abnormal versus normal HRR. HRR was significantly associated with both
CRP (r = -0.33, p < 0.001) and WBCs (r = -0.29, p < 0.001), although in a stepwise multiple regression
HRR resulted independently associated with CRP (beta = -0.151, p = 0.001) alone. In a logistic multivariate
model, the group within the highest quartile of CRP (odds ratio 1.59, 95% CI 1.07–2.33) was more likely
to have abnormal HRR than those within the lowest quartile.
Conclusion: Abnormal HRR and inflammatory markers are closely associated in PCOS women acting
probably in concert to increase the cardiovascular risk profile of these patients.
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Mounting evidences suggest that polycystic ovary syn-
drome (PCOS) is a complex endocrine-metabolic disease
strictly associated with long-term cardiovascular risk [1,2].
In fact, PCOS women, even at young age, have a clustering
of cardiovascular risk factors [3-7] suggesting that they
represent a group with an increased risk for developing
early-onset cardiovascular disease [2,8].
Heart rate recovery (HRR) is an easily-obtained measure
derived from exercise stress test and is defined as the fall
in heart rate during the first minute after maximal exercise
[9]. The underlying mechanisms by which slow HRR after
exercise is associated to an increased risk for cardiovascu-
lar mortality [10] are not fully understood. Because the
rapid decrease in heart rate immediately after exercise is
primarily due to vagal reactivation [11-13], slow HRR may
be indicative of decreased autonomic nervous system
activity.
In a recent study, PCOS women showed slower HRR
when compared to healthy controls [14]. Notably, slower
HRR was inversely associated to body mass index (BMI)
and to markers of insulin resistance, suggesting a close
and complex relationship between autonomic function
and glucose metabolism in PCOS women [2,14].
Inflammation plays a key role in the pathophysiological
mechanism of atherosclerosis [15,16] and cardiovascular
disease [17]. Several inflammation markers, such as C-
reactive protein (CRP), interleukin 6, soluble intercellular
adhesion molecule type 1, and white blood cells (WBCs)
count, are found to be significant predictors of the risk of
coronary heart disease and future cardiovascular events
[18]. Inflammation may also be associated with the met-
abolic syndrome [19,20] and increases WBCs count [21].
Cross-sectional studies have suggested that cardiac auto-
nomic nervous activity, as assessed by heart rate variabil-
ity, is related to inflammatory markers such as CRP and
WBCs count [22,23]. Experimental studies reported that
vagal nerve stimulation can modulate inflammatory
cytokines through the cholinergic anti-inflammatory
pathway [24,25], thus suggesting that HRR may be related
to inflammatory markers.
Based on these considerations, the current study was
designed to study the relationships between HRR and




Two-hundred forty-three PCOS patients were recruited at
the Department of Molecular and Clinical Endocrinology
and Oncology in Naples (Italy) among those who consec-
utively visited the ambulatory from January 2005 to
March 2008.
All PCOS patients achieved the European Society for
Human Reproduction and Embryology/American Society
for Reproductive Medicine criteria for the PCOS diagnosis
[26]. Polycystic ovaries were identified by transvaginal
ultrasonography examination [26] and hirsutism by Fer-
riman-Gallwey score > 8.
Exclusion criteria included pregnancy, glucose intolerance
[as screened by a 2-hour oral glucose tolerance test
(OGTT)] and diabetes, hypothyroidism, hyperprolactine-
mia, Cushing's syndrome, non-classical congenital adre-
nal hyperplasia, and use of oral contraceptives,
glucocorticoids, antiandrogens, ovulation induction
agents, antidiabetic, antipsychotic and antiobesity drugs
or other hormonal drugs and antihypertensive within the
previous 6 months. Subjects with neoplastic, hepatic, res-
piratory and any cardiovascular disorder or other concur-
rent medical illness (i.e. respiratory and heart failure and
renal disease) were also excluded from the study.
The study was conducted according to the guidelines of
the Declaration of Helsinki, and the Institutional Ethical
committee approved the study protocol. The purpose of
the protocol was explained to each subject, and written
informed consent was obtained from each patient before
the screening. The study had no external funding source.
Biochemical Assays
All blood samples were obtained in the morning between
08.00 h and 09.00 h after an overnight fasting during the
early follicular phase (2nd–4th day) of progesterone-
induced menstrual cycle. Blood samples were collected
into tubes containing EDTA after a 30-min resting period
in the supine position. All blood samples were immedi-
ately centrifuged at 4°C for 20 min at 1600 g, and stored
at -20°C until assayed.
Plasma LH, FSH, prolactin (PRL), estradiol (E2), P, 17α-
hydroxyprogesterone (17-OH-P), T, androstenedione
(Δ4), and DHEA-S levels were measured by specific radio-
immunoassays (RIA) as previously described [3-6]. The
levels of SHBG were measured using an IRMA [3-6], and
the free androgen index (FAI) was calculated [T(nmol/l)/
SHBG(nmol/l) × 100].
Blood insulin and glucose levels were measured by a
solid-phase chemiluminescent enzyme immunoassay and
the glucose oxidase method, respectively [3-6]. The glu-
cose and insulin areas under curve (AUC) for glucose
(AUCGLU) and for insulin (AUCINS), and the AUCGLU/Page 2 of 7
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culated.
The lipid profile consisted of serum total cholesterol (TC),
high-density lipoprotein-cholesterol (HDL-C), low-den-
sity lipoprotein-cholesterol (LDL-C) and triglycerides
(TG) levels as previously described [3-6]. WBCs count and
CRP were measured as previously described [4,7]. Inter-
and intra-assay coefficients of variation were < 5% for all
blood variables.
Cardiopulmonary exercise test and HRR evaluation
PCOS women underwent a symptom-limited CPX with
Bruce treadmill protocol [6]. Heart rate (HR) and blood
pressure (BP) at baseline and peak exercise, heart rate 1
minute into a walking cool-down period (1.7 mph at 0%
grade), and treadmill speed and grade at peak exercise
were recorded as previously reported [14].
HRR was calculated as the difference between heart rate at
peak exercise and heart rate at first minute of the cool-
down period.
Abnormal HRR, determined in our population by finding
the maximum value for the log-rank chi-square test statis-
tic for all possible cutoff points across percentiles, was
defined as ≤18 beats/min [9].
Respiratory gas exchange measurements were obtained
breath-by-breath with use of a computerized metabolic
cart (Vmax 29C, Sensormedics, Yorba Linda, CA) as previ-
ously described [6].
Statistics
Data are expressed as mean ± standard deviation for con-
tinuous variables and as counts and proportions for cate-
gorical variables. Two group comparisons were performed
using independent Student's t tests for continuous varia-
bles and the chi-square test for categorical variables. CRP
values were log transformed because of non-normal dis-
tribution. Pearson's correlations, stepwise multiple regres-
sion analysis, and analysis of variance were used to
determine the relation between HRR and inflammatory
markers. The selection of variables for entrance into the
multivariate model was based on the univariate analysis.
We tested potential collinearity among covariates using
Pearson's correlations. After these evaluations, we selected
the non-collinear variables for multivariable models: age,
BMI, AUCINS, fasting glucose, TC, HDL-C, TG, HRREST, and
VO2peak. Logistic regression was used to evaluate the asso-
ciation between abnormal HRR (yes or no) and quartiles
of CRP and WBCs count (categorical data). Statistical sig-
nificance was set at p < 0.05 for all data. Statistical analy-
ses were performed using SPSS version 13.0 (SPSS, Inc.,
Chicago, IL).
Results
Group comparisons according to abnormal HRR (≤18
beats/min) are listed in Table 1. Abnormal HRR was
found in 89 patients of 243 (36.6%). Patients with abnor-
mal HRR had significantly greater levels of CRP (p <
0.001), and WBCs (p < 0.001), but not TC and LDL-C,
than subjects with normal HRR.
Using Pearson's correlations, HRR was significantly asso-
ciated with age (r = -0.28, p < 0.001), BMI (r = -0.49, p <
0.001), AUCINS (r = -0.44, p < 0.001), HDL-C (r = 0.26, p
< 0.001), TG (r = -0.28, p < 0.001), HRREST (r = -0.31, p <
0.001), VO2peak (r = 0.51, p < 0.001), logCRP (r = -0.33, p
< 0.001) and WBCs (r = -0.29, p < 0.001). For anthropo-
metrical, metabolic and cardiopulmonary profile of the
PCOS population according to HRR, see Table 2.
Table 1: Hormonal characteristics of the PCOS population according to HRR.
Variables Normal HRR (n = 154)
(> 18 beats/min)
Abnormal HRR (n = 89)
(≤18 beats/min)
P value
Ferriman-Gallwey score 11.9 ± 3.5 12.1 ± 3.4 0.678
FSH (IU/liter) 10.5 ± 1.7 10.1 ± 1.6 0.725
LH (IU/liter) 24.2 ± 3.3 23.5 ± 3.1 0.811
PRL (ng/ml) 10.5 ± 1.3 10.2 ± 1.1 0.797
E2 (pmol/liter) 120 ± 30.5 118 ± 26.1 0.502
P (nmol/liter) 1.2 ± 0.4 1.3 ± 0.6 0.630
17-OHP (nmol/liter) 1.6 ± 0.3 1.5 ± 0.4 0.809
T (nmol/liter) 2.3 ± 0.7 2.5 ± 0.5 0.649
A (nmol/liter) 5.1 ± 0.7 5.3 ± 0.9 0.702
DHEAS (μmol/liter) 4320 ± 465 4290 ± 441 0.488
SHBG (nmol/liter) 27 ± 6.2 29 ± 6.5 0.549
FAI 8.5 ± 3.4 8.6 ± 3.6 0.882
Abbreviations: A, Androstenedione; DHEAS, dehydroepiandrosterone sulphate; E2, Estradiol; FAI, free androgen index; FSH, follicle stimulating 
hormone; HRR, heart rate recovery; LH, luteinizing hormone; P, progesterone; PRL, prolactin; SHBG, Sex Hormone Binding Globulin; T, 
testosterone; 17-OHP, 17α-hydroxyprogesterone.Page 3 of 7
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beat/min) was independently associated with logCRP
(Table 3). Subjects were divided into quartiles according
to HRR (quartile 1: < 18 beats/min; quartile 2: 18 to 24
beats/min; quartile 3: 25 to 30 beats/min; quartile 4: > 30
beats/min).
The levels of logCRP and WBCs in each quartile were 1.26
± 0.2, 1.13 ± 0.2, 1.05 ± 0.1, and 1.02 ± 0.1 mg/dl (Figure
1) and 6.74 ± 2.3, 6.29 ± 1.5, 6.02 ± 1.5, and 5.77 ± 1.3 ×
109 cells/l (Figure 2) in quartiles 1 to 4, respectively. There
were significant differences among quartiles 1 to 4 for
logCRP (p < 0.05) and WBCs count (p < 0.05).
To evaluate the association between abnormal HRR and
inflammatory markers, subjects were divided into quar-
tiles according to logCRP and WBCs count. In a logistic
multivariate model (adjusted for age, BMI, TC, HDL-C,
TG, fasting glucose, AUCINS, HRREST and VO2peak) the
group within the highest quartile of log CRP and WBCs
count was more likely to have abnormal HRR than the
group within the lowest quartile of log CRP and WBCs
count (Table 4).
Table 2: Anthropometrical, metabolic and cardiopulmonary profile of the PCOS population according to HRR.
Variables Normal HRR (n = 154)
(> 18 beats/min)
Abnormal HRR (n = 89)
(≤18 beats/min)
P value
Age (years) 20.7 ± 2.3 23.9 ± 1.9 < 0.001
BMI (Kg/m2) 27.3 ± 2.9 31.3 ± 3.1 < 0.001
WHR 0.84 ± 0.2 0.87 ± 0.1 < 0.001
TC (mg/dl) 153.3 ± 18.1 155.8 ± 16.6 0.442
HDL-C (mg/dl) 44.2 ± 7.3 40.9 ± 10.5 < 0.001
LDL-C (mg/dl) 89.5 ± 8.3 90.4 ± 7.6 0.593
TG (mg/dl) 114.6 ± 20.3 122 ± 22.4 < 0.001
Fasting glucose 93.0 ± 6.8 98.3 ± 7.1 < 0.001
Fasting insulin 20.1 ± 3.3 24.2 ± 3.7 < 0.001
AUCGLU 11950 ± 2122 12033 ± 2154 0.335
AUCINS 16520 ± 950 17480 ± 970 < 0.001
AUCGLU/INS 0.77 ± 0.2 0.73 ± 0.3 < 0.001
WBCs count (× 109 cells/l) 6.6 ± 1.5 7.3 ± 1.8 < 0.001
CRP (mg/dl) 0.11 (0.09–0.25) 0.21 (0.11–0.69) < 0.001
logCRP (mg/dl) 1.1 ± 0.4 1.8 ± 0.7 < 0.001
HRREST (beats/min) 67.2 ± 2.5 72.1 ± 3.9 < 0.001
VO2peak (ml/Kg/min) 26.1 ± 3.3 22.5 ± 2.8 < 0.001
Abbreviations: AUCGLU, area under the curve for glucose; AUCINS, area under the curve for insulin; BMI, body mass index; CRP, C-reactive protein; 
HDL-C, high density lipoprotein cholesterol; HRR, heart rate recovery; HRREST, resting heart rate; LDL-C, low density lipoprotein cholesterol; TC, 
total cholesterol; TG, triglycerides; VO2max, maximal oxygen consumption; WBCs, white blood cells; WHR, waist to hip ratio.
Table 3: Stepwise multiple regression analysis for log C-reactive 
protein.
Variables β Coefficient SE P value
HRR* -0.151 0.001 0.001
Fasting glucose 0.039 0.001 0.005
AUCINS -0.136 0.001 0.001
BMI 0.126 0.003 0.001
VO2max -0.139 0.001 0.001
HDL-C -0.177 0.001 0.001
TG -0.141 0.001 0.001
HRREST 0.108 0.002 0.001
Regression analysis included age, BMI, TC, HDL-C, LDL-C, TG, fasting 
glucose, AUCINS, HRREST, HRR, and VO2max as covariates. 
Abbreviations: AUCINS, area under the curve for insulin; BMI, body 
mass index; HDL-C, high density lipoprotein cholesterol; HRREST, 
resting heart rate; HRR, heart rate recovery; TC, total cholesterol; 
TG, triglycerides; VO2max, maximal oxygen consumption. *Each 1 
beat/min.
Mean comparison of logCRP by quartile (Q) of HRRFigure 1
Mean comparison of logCRP by quartile (Q) of HRR. 
*Significantly different from Q4 (p < 0.05).Page 4 of 7
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This study describes a significant association between post
exercise slow HRR and increased levels of inflammatory
markers in young PCOS women.
Post exercise HRR has been demonstrated as a risk factor
for cardiovascular and all-cause mortality in healthy
adults [10,28,29], in individuals with CVD [30] in indi-
viduals with risk factors for CVD [31,32] and in men with
diabetes [33]. HRR is positively associated with insulin
sensitivity as measured with a hyperinsulinemic-euglyc-
emic clamp and metabolic syndrome in elderly men [34]
as well as in middle-aged men and women [35-38].
HRR has also been found to be associated with individual
components of the metabolic syndrome, such as blood
glucose [36] low HDL-C [34,35] and resting systolic and
diastolic blood pressure [35]. Panzer et al. [36] demon-
strated a strong inverse relationship between fasting
plasma glucose and HRR even at non-diabetic levels
among middle-aged healthy men and women. Moreover,
HRR has been shown to be inversely associated with trig-
lyceride/HDL-C ratio in middle-aged healthy men and
women [37].
Although IR is not a key criterion to diagnose PCOS [26],
there is a wide consensus that subjects with PCOS are
more insulin resistant than healthy women. IR has been
found to be significantly associated with impaired cardi-
opulmonary functional capacity [6,7,38]. Moreover,
abnormal HRR was significantly associated to BMI and to
AUCINS (a powerful marker of IR), suggesting that
impaired glucose metabolism in young overweight PCOS
women might be a determinant of autonomic dysfunc-
tion [14]. Unfortunately, the cross sectional nature of the
present study does not allow the evaluation of a causal
association between autonomic dysfunction and IR and
the elucidation of the mechanisms involved in the patho-
genesis of both conditions.
It is known that inflammation plays an important role in
the development and progression of atherosclerosis [39],
and inflammatory markers such as CRP and WBCs count
are strong predictors of cardiovascular events in healthy
populations as well as patients with coronary heart dis-
ease [40].
Higher CRP levels and WBCs count have been described
[4,7] in a wide PCOS women population suggesting an
increased cardiovascular risk profile in these patients [2].
Observational studies showed a decreased autonomic
nervous system activity related to inflammatory markers
[22,23]. Recent experimental evidences suggest a role for
the parasympathetic nervous system in the direct regula-
tion of inflammation, pointing to the existence of a
cholinergic anti-inflammatory reflex [24,25]. Recently,
Vieira et al. [41] reported that post exercise HRR is inde-
pendently associated with lower CRP in older sedentary
individuals, suggesting an involvement of parasympa-
thetic nervous system in regulating chronic inflammation
Mean comparison of white blood cells (WBCs) count by quartile (Q) of heart rate rec very (HRR)Figur 2
Mean comparison of white blood cells (WBCs) count 
by quartile (Q) of heart rate recovery (HRR). *Signifi-
cantly different from Q4 (p < 0.05).
Table 4: Multivariate-adjusted odds ratios (95% confidence interval) for abnormal heart rate recovery (HRR) by quartile of log C-
reactive protein (log CRP) and white blood cells (WBCs) count
Variable Quartile 1 (Reference) Quartile 2 Quartile 3 Quartile 4
logCRP (mg/dl) (n = 67) ≤0.8 (n = 75) 0.81–1.19 (n = 53) 1.2–1.5 (n = 48) ≥1.5
Crude model 1.00 1.44 (1.21–1.86) 2.23 (1.73–2.88) 3.41 (2.42–4.25)
Adjusted model 1.00 1.19 (0.81–1.63) 1.34 (0.93–1.99) 1.59 (1.07–2.33)
WBCs count (× 109 cells/l) (n = 62) ≤5.0 (n = 71) 5.1–6.0 (n = 58) 6.1–7.0 (n = 52) ≥7.1
Crude model 1.00 1.41 (1.14–1.93) 1.95 (1.48–2.65) 2.77 (2.19–3.58)
Adjusted model 1.00 1.38 (1.06–2.12) 1.33 (0.97–1.96) 1.61 (1.14–2.46)
Crude model is unadjusted. Adjusted model includes age, BMI, TC, HDL-C, TG, fasting glucose, AUCINS, HRREST, and VO2peak.
Abbreviations: AUCINS, area under the curve for insulin; BMI, body mass index; CRP, C-reactive protein; HDL-C, high density lipoprotein 
cholesterol; logCRP, logarithmic transformation of CRP values; HRREST, resting heart rate; TC, total cholesterol; TG, triglycerides; VO2max, maximal 
oxygen consumption; WBCs, white blood cells.Page 5 of 7
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that the reduced cardiac adrenergic activity (evaluated by
iodine-123-labeled metaiodobenzylguanidine uptake)
observed in patients with glucose intolerance was associ-
ated to elevated pro-inflammatory cytokine levels [42].
The association between autonomic nervous system and
systemic inflammation in young PCOS women after
adjustment for common cardiovascular and metabolic
confounders shed light on the complex mechanisms and
the possible therapeutic strategies related to this endo-
crine-cardiometabolic disease.
Experimental and clinical evidences suggest that exercise
training is an effective therapeutic intervention aimed at
improving autonomic function as well as cardiopulmo-
nary functional capacity [43-45]. In PCOS women, the
exercise-induced improvement of cardiopulmonary and
autonomic function should have been addressed to the
improvement in insulin sensitivity, to the reduction in
BMI, and to the powerful anti-inflammatory effect of
training [46,47]. However, exercise training should be
continued regularly in order to maintain the described
beneficial effects [48].
Our previous prospective controlled data [46-48], in fact,
confirmed that exercise training is effective in reducing
BMI and improving insulin sensitivity markers in PCOS
women, even thought no significant changes in sex hor-
mones were observed. At this regard, it could be possible
to hypothesize that the exercise induced improvement of
autonomic function is mediated by BMI reduction and
insulin sensitivity improvement.
Recently, Thompson et al. [49] studied the effect of weight
loss on HRR in overweight and obese PCOS patients. After
10 weeks of diet, a significant improvement in HRR was
observed in concert with a reduction in body weight, waist
circumference, blood pressure, fasting insulin and glucose
levels, HOMA score, T, FAI, and with an increase in SHBG
[49]. In addition, HRR was significantly related to the
reduction in body weight and waist circumference [49].
These findings demonstrated that weight loss can exert a
beneficial role in reducing the cardiovascular risk in PCOS
patients also improving the autonomic function [49].
Given the cross-sectional nature of the present study, it
cannot be determined whether impaired autonomic func-
tion is the cause or effect of systemic inflammation. A
potential limitation of our data is that we did not control
for diet status, which may potentially confound the rela-
tion between HRR and inflammation markers. Because of
the relation between cardiopulmonary functional capac-
ity and HRR, strength of this study is the use of directly
measured peak oxygen uptake as a covariate.
Conclusion
In young PCOS women, abnormal HRR after exercise test-
ing is significantly and closely associated to inflammatory
markers, i.e. CRP and WBCs. These findings could suggest
that in women with PCOS several alterations could act in
concert contributing to increase cardiovascular risk profile
of these patients.
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